A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.
Experimental Treatment Gaining Popularity Via Social Media
The experimental drug, which is still in research studies, is being advertised by social media influencers for its alleged weight-reducing properties. Followers are encouraged to contact these accounts directly for source information, while also obtaining discount codes.
Active Trade on Social Networks
Additionally, a robust trade exists on Telegram, where groups with numerous of members share “before and after” images, injection guides and claims of rapid British shipping. Vendors market the drug there before directing customers to other platforms for transactions.
Understanding The Experimental Drug
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The drug targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could help patients reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the successor to Ozempic.
Medical Professionals Voice Worries
Nevertheless, physicians and pharmacists have warned that the distribution of what remains an unlicensed medication in the United Kingdom is worrisome and could lead to individuals administering substances of uncertain source.
Some professionals said the popularity for retatrutide could be connected to the increasing cost of approved weight loss treatments such as Mounjaro.
Regulatory Status and Implementation
Selling retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be promoted or distributed for personal consumption under the British medical regulations.
Several influencers attempt to circumvent the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still breach medicines, marketing, and consumer regulations, potentially leading to fines, legal action or imprisonment.
Platform Response and Content Removal
According to the social media company, the service has taken down violative content and prohibited related keywords and search suggestions. The company said it was dedicated to keeping the platform secure and investing in enhancing enforcement strategies.
Online Trading Activities
Investigations also discovered groups with up to 9,000 members marketing retatrutide using Telegram's built-in discovery tool, which operates like a public directory. Typing “retatrutide” instantly brings up groups with numerous of users, filled with photos of slimming results, glowing reviews and step-by-step guides for preparing or injecting at home.
After minutes of joining one group, a vendor shared WhatsApp details, where the majority of purchases take place. The seller provided an instruction manual and promised delivery within two days. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another shared a image of a alleged testing documentation. Not one asked about body mass, health issues or past usage.
Product Information and Costs
Inside these groups, posts show dark colored parcels with Royal Mail labels, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, prepared at home with purified liquid, or ready-to-use pens usually priced at 160 pounds for 20 milligrams. When asked how long a pen should be used, sellers give contradictory answers ranging from a few weeks to “depends on your body”.
Platform Oversight and Safety Measures
A representative for Telegram stated it actively monitored harmful material on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“Individuals are administering materials they can’t verify. Although the science behind this drug is sound, these online versions may not include what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to recent price rises for approved slimming medications such as Mounjaro. “With prices rising, individuals are turning to social media. But counterfeit injections are highly risky. You cannot know what’s inside or whether the conditions they were made in was clean,” she explained.
Her staff has previously encountered patients harmed by self-injection from unverified sources. “We recognize the frustration, but purchasing from Telegram or communication platforms is taking chances with your well-being,” stated the doctor. “These substances could be impure or improperly measured.”
Producer Position
A representative from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Therefore at this time no one can market [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a company experimental substance not yet approved … may subject patients to potentially significant medical dangers”.
